Document Detail


Oral antiplatelet therapy in stroke prevention. Minireview.
MedLine Citation:
PMID:  21048805     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
BACKGROUND: Antiplatelet therapy plays a crucial role in the primary and secondary prevention of noncardioembolic ischemic stroke / transient ischemic attacks (IS/TIA). Several antiplatelet agents are available. This review deals with the characteristics of particular antiplatelet agents as well as choice of antiplatelet treatment in various situations, based on the evidence and international recommendations.
METHODS: PubMed and Stroke Trials Registry on-line databases and the European Stroke Organisation Guidelines for Management of IS/TIA 2008 and update of the recommendations of the American Heart Association / American Stroke Association Council 2008 on Stroke were used.
RESULTS: Acetylsalicylic acid (ASA) is the only antiplatelet drug used in primary prevention, mainly to reduce the risk of myocardial infarction (MI), but also in women aged 45 years or more and in some patients with non-valvular atrial fibrillation to reduce risk of IS/TIA. In the secondary prevention of noncardioembolic IS/TIA, ASA in combination with long release dipyridamole (DIP) and clopidogrel (CLOP) alone are considered first choice therapies. The choice of the particular antiplatelet agent should be individualized according to the patient risk factor profiles and treatment tolerance. ASA alone or triflusal can be used alternatively in patients who cannot be treated with either ASA+DIP or CLOP. The use of indobufen should be considered only in patients in need of temporary interruption of the antiplatelet therapy. Ticlopidine (TIC) should not be newly introduced into the treatment. Currently, insufficient data are available on the use of cilostazol in IS/TIA prevention.
Authors:
Michal Kral; Roman Herzig; Daniel Sanak; David Skoloudik; Ivanka Vlachova; Andrea Bartkova; Petr Hlustik; Michal Kovacik; Petr Kanovsky
Related Documents :
18799875 - Brain natriuretic peptide as a surrogate marker for cardioembolic stroke with paroxysma...
18848685 - Absence of recurrent stroke after percutaneous closure of patent foramen ovale despite ...
19696415 - First food and drug administration-approved prospective trial of primary intracranial s...
1868405 - Prevention and management of medical complications of the hospitalized elderly stroke p...
17640535 - Epidemiology of myocardial infarction.
10813385 - Effects of prolonged propranolol treatment on left ventricular remodeling and oxidative...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia     Volume:  154     ISSN:  1213-8118     ISO Abbreviation:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-11-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101140142     Medline TA:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub     Country:  Czech Republic    
Other Details:
Languages:  eng     Pagination:  203-10     Citation Subset:  IM    
Affiliation:
Stroke Center, Department of Neurology, Palacky University and University Hospital, Olomouc, Czech Republic. kral_michal@centrum.cz
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Collagenous repeat-containing sequence of 26 kDa protein - a newly discovered adipokine - sensu lato...
Next Document:  An original histological method for studying the volar skin of the fetal hands and feet.